Canada-based Winterlight Labs has raised $4.23m (C$5.6m) through a Series A round to develop its artificial intelligence (AI) vocal technology to detect central nervous system disorders and track the efficacy of treatments.

Hikima Ventures, the venture capital arm of Hikima Pharmaceuticals, led the funding round, which also saw participation from investors such as First Star Ventures, Pacific Health Ventures and existing investor, Grey Sky Venture Partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Winterlight Labs is developing its AI technology that combines computational linguistics, cognitive neuroscience and machine learning to analyse the cognitive health of patients.

Winterlight’s tablet-based tool makes use of speech-based evaluation that helps healthcare experts to identify the vocal biomarkers, which serve as indicators for any cognitive changes.

Through analysis of a one-minute sample of a patient’s natural speech, Winterlight’s method can detect cognitive and mental disorders such as dementia, as well as track treatment effectiveness.

Hikma Ventures managing director Lana Ghanem said: “We are very excited to enter into the field of vocal diagnostics by leading the investment in Winterlight Labs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We recognise the global potential of voice analysis for the diagnosis, monitoring and ongoing treatment of various diseases and look forward to working with the team and our co-investors to help advance the technology and expand disease areas and geographies covered, especially in the Middle East and North Africa.”

Proceeds from the funding will be used to extend Winterlight’s technology to add other indications, such as schizophrenia and multiple sclerosis.

Hikma Ventures invests in emerging companies in the digital health market, with the potential to boost its market intelligence and future pipeline.